Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.75 | N/A | -47.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.75 | N/A | -47.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the current market conditions. They highlighted ongoing efforts to navigate through these challenges.
Management acknowledged the challenges faced this quarter.
They emphasized the need for continued focus on strategic initiatives.
PTC Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 4.9% following the earnings report, possibly due to investor optimism about future developments. The lack of revenue data and guidance may leave some uncertainty about the company's immediate prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARRIOTT INTL INC NE Class A
Aug 5, 2019